View Past PerformanceBioethics バランスシートの健全性財務の健全性 基準チェック /06Bioethicsの総株主資本は$-931.2K 、総負債は$585.7Kで、負債比率は-62.9%となります。総資産と総負債はそれぞれ$14.7Kと$945.9Kです。主要情報-62.89%負債資本比率US$585.69k負債インタレスト・カバレッジ・レシオn/a現金US$14.66kエクイティ-US$931.22k負債合計US$945.88k総資産US$14.66k財務の健全性に関する最新情報お知らせ • Apr 01Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2025, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 15Bioethics, Ltd. announced delayed 10-Q filingOn 08/14/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17Bioethics, Ltd. announced delayed 10-Q filingOn 05/15/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 02Bioethics, Ltd. announced delayed annual 10-K filingOn 04/01/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2023, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.すべての更新を表示Recent updatesお知らせ • Apr 01Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2025, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 15Bioethics, Ltd. announced delayed 10-Q filingOn 08/14/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 27SILQ Technologies Corporation entered into a non-binding letter of intent to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction.SILQ Technologies Corporation entered into a non-binding letter of intent to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction on June 18, 2024. All outstanding shares of SILQ would then be converted into shares of Bioethics common stock pursuant to the definitive merger agreement. Following the closing of the transaction, the parties’ current intention and expectation as set out in the Letter of Intent is that the stockholders of SILQ would own approximately 89% of the fully diluted total outstanding stock of Bioethics, and the stockholders of Bioethics immediately prior to the closing of the transaction, including all current stockholders and all shares to be issued prior to the closing as more fully described in the Letter of Intent, would own 11% of the total outstanding stock of Bioethics following the transaction. In connection with the proposed Merger, Bioethics has agreed to consummate a 1-for-2 reverse stock split. Prior to the proposed Merger, Bioethics intends to issue common or preferred stock convertible into common stock in order to raise money to pay down debt and incentivize and otherwise compensate Bioethics’ officers, directors and consultants, who have not received cash compensation for years. It is currently anticipated that following the closing of the proposed Merger, that there will be at least 50,450,000 shares of Bioethics common stock issued an outstanding. This anticipated post-transaction outstanding stock will include the current outstanding shares of Bioethics after a 1-for-2 reverse stock split, meaning that the ownership of Bioethics of the current Bioethics stockholders, exclusive of all shares to be issued between now and the closing of the transaction, as a percentage of all anticipated outstanding stock will be approximately 1% of all outstanding Bioethics stock following the closing of the transaction. The transaction is subject to due diligence review.お知らせ • May 17Bioethics, Ltd. announced delayed 10-Q filingOn 05/15/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 02Bioethics, Ltd. announced delayed annual 10-K filingOn 04/01/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2023, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 16Bioethics, Ltd. announced delayed 10-Q filingOn 05/15/2023, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 16Bioethics, Ltd. announced delayed 10-Q filingOn 08/15/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17Bioethics, Ltd. announced delayed 10-Q filingOn 05/16/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 01Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Aug 17Bioethics, Ltd. announced delayed 10-Q filingOn 08/16/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 18Bioethics, Ltd. announced delayed 10-Q filingOn 05/17/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 02Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 17Bioethics, Ltd. announced delayed 10-Q filingOn 11/16/2020, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 06XCR Diagnostics, Inc. entered into a non-binding term sheet to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction.XCR Diagnostics, Inc. entered into a non-binding term sheet to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction on July 29, 2020. Pursuant to the term sheet, Bioethics will issue 34.2 million shares of Bioethics common stock post one-for-ten reverse stock split. Bioethics and certain of its creditors and affiliates agree to settle down all the liabilities of Bioethics except for $0.2 million. Post completion of the transaction and reverse stock split stockholders of XCR Diagnostics will have the majority share of Bioethics and XCR Diagnostics will become a financially consolidated subsidiary of Bioethics. Mark Scharmann and Elliott Taylor affiliates of Bioethics agrees to lock-up/leak-out agreement governing their shares. Bioethics will raise at least $0.3 million in a private placement within 90 days of closing. At closing, directors of Bioethics and XCR Diagnostics will resign and XCR Diagnostics will have the right to appoint all the directors of Bioethics. The initial directors are expected to be Mark Powelson, Mark Bagnall, Bruce Chafin, Chuck Morrison and Lynda Merrill. Board advisors will be Brian Caplin and Mark Scharmann. The transaction closing is subject to completion of due diligence of XCR Diagnostics by Bioethics, execution of reverse stock split, execution of definitive agreement document, obtaining necessary third party approvals, approval of the board of Bioethics and XCR Diagnostics, approval by the shareholders of Bioethics and XCR Diagnostics and the term sheet requires Bioethics to complete the private placement. The transaction is expected to close by or before August 28, 2020.財務状況分析短期負債: BOTHは マイナスの株主資本 を有しており、これは 短期資産 が 短期負債 をカバーしていないことよりも深刻な状況です。長期負債: BOTHは株主資本がマイナスであり、これは短期資産が 長期負債 をカバーしていないことよりも深刻な状況です。デット・ツー・エクイティの歴史と分析負債レベル: BOTHは 株主資本がマイナス となっており、これは高い負債レベルよりも深刻な状況です。負債の削減: BOTHの株主資本はマイナスなので、時間の経過とともに負債が減少したかどうかを確認する必要はありません。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: 現在のフリーキャッシュフローに基づいて、 BOTHに十分なキャッシュランウェイがあるかどうかを判断するにはデータが不十分です。キャッシュランウェイの予測: BOTHの フリー キャッシュ フロー が過去のレートに基づいて増加または減少し続ける場合、十分な キャッシュ ランウェイ があるかどうかを判断するためのデータが不十分です。健全な企業の発掘7D1Y7D1Y7D1YDiversified-financials 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/02/10 14:04終値2025/11/13 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bioethics, Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 01Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2025, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 15Bioethics, Ltd. announced delayed 10-Q filingOn 08/14/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17Bioethics, Ltd. announced delayed 10-Q filingOn 05/15/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 02Bioethics, Ltd. announced delayed annual 10-K filingOn 04/01/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2023, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 01Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2025, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 15Bioethics, Ltd. announced delayed 10-Q filingOn 08/14/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 27SILQ Technologies Corporation entered into a non-binding letter of intent to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction.SILQ Technologies Corporation entered into a non-binding letter of intent to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction on June 18, 2024. All outstanding shares of SILQ would then be converted into shares of Bioethics common stock pursuant to the definitive merger agreement. Following the closing of the transaction, the parties’ current intention and expectation as set out in the Letter of Intent is that the stockholders of SILQ would own approximately 89% of the fully diluted total outstanding stock of Bioethics, and the stockholders of Bioethics immediately prior to the closing of the transaction, including all current stockholders and all shares to be issued prior to the closing as more fully described in the Letter of Intent, would own 11% of the total outstanding stock of Bioethics following the transaction. In connection with the proposed Merger, Bioethics has agreed to consummate a 1-for-2 reverse stock split. Prior to the proposed Merger, Bioethics intends to issue common or preferred stock convertible into common stock in order to raise money to pay down debt and incentivize and otherwise compensate Bioethics’ officers, directors and consultants, who have not received cash compensation for years. It is currently anticipated that following the closing of the proposed Merger, that there will be at least 50,450,000 shares of Bioethics common stock issued an outstanding. This anticipated post-transaction outstanding stock will include the current outstanding shares of Bioethics after a 1-for-2 reverse stock split, meaning that the ownership of Bioethics of the current Bioethics stockholders, exclusive of all shares to be issued between now and the closing of the transaction, as a percentage of all anticipated outstanding stock will be approximately 1% of all outstanding Bioethics stock following the closing of the transaction. The transaction is subject to due diligence review.
お知らせ • May 17Bioethics, Ltd. announced delayed 10-Q filingOn 05/15/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 02Bioethics, Ltd. announced delayed annual 10-K filingOn 04/01/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2023, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 16Bioethics, Ltd. announced delayed 10-Q filingOn 05/15/2023, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 16Bioethics, Ltd. announced delayed 10-Q filingOn 08/15/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17Bioethics, Ltd. announced delayed 10-Q filingOn 05/16/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 01Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Aug 17Bioethics, Ltd. announced delayed 10-Q filingOn 08/16/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 18Bioethics, Ltd. announced delayed 10-Q filingOn 05/17/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 02Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 17Bioethics, Ltd. announced delayed 10-Q filingOn 11/16/2020, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 06XCR Diagnostics, Inc. entered into a non-binding term sheet to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction.XCR Diagnostics, Inc. entered into a non-binding term sheet to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction on July 29, 2020. Pursuant to the term sheet, Bioethics will issue 34.2 million shares of Bioethics common stock post one-for-ten reverse stock split. Bioethics and certain of its creditors and affiliates agree to settle down all the liabilities of Bioethics except for $0.2 million. Post completion of the transaction and reverse stock split stockholders of XCR Diagnostics will have the majority share of Bioethics and XCR Diagnostics will become a financially consolidated subsidiary of Bioethics. Mark Scharmann and Elliott Taylor affiliates of Bioethics agrees to lock-up/leak-out agreement governing their shares. Bioethics will raise at least $0.3 million in a private placement within 90 days of closing. At closing, directors of Bioethics and XCR Diagnostics will resign and XCR Diagnostics will have the right to appoint all the directors of Bioethics. The initial directors are expected to be Mark Powelson, Mark Bagnall, Bruce Chafin, Chuck Morrison and Lynda Merrill. Board advisors will be Brian Caplin and Mark Scharmann. The transaction closing is subject to completion of due diligence of XCR Diagnostics by Bioethics, execution of reverse stock split, execution of definitive agreement document, obtaining necessary third party approvals, approval of the board of Bioethics and XCR Diagnostics, approval by the shareholders of Bioethics and XCR Diagnostics and the term sheet requires Bioethics to complete the private placement. The transaction is expected to close by or before August 28, 2020.